Skip to content
DraconiticResearch
Search Sources API
182,469 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY-NC-ND 4.0The Medical Journal of Australia

Short‐Term Adverse Events Following Recombinant Zoster Vaccination in Older Adults in Australia: A Survey Study Comparing Dose 1 and Dose 2 and Influence of Dose Interval

  • Lucy Dawes1,2
  • Thuy Nguyen1,2
  • Kristine Macartney1,2
  • Lucy Deng1,2
  1. 1National Centre for Immunisation Research and Surveillance Sydney New South Wales Australia
  2. 2Children's Hospital Westmead Clinical School University of Sydney Sydney New South Wales Australia
Read full textPDFDOICite

Abstract

Self‐reported adverse events following first and second recombinant zoster vaccination (RZV) doses in older adults (n = 41,069) collected through AusVaxSafety were analysed. Adverse event rates were higher following Dose 2 (54%; 95% CI, 53%–54%) than after Dose 1 (45%; 95% CI, 45%–46%), particularly with 3–6‐ and 7–9‐month dose intervals, although medical review rates remained low (1.1%; 95% CI, 1.0%–1.2%), suggesting RZV is reactogenic but with no serious outcomes.

Related

  1. Transient clinical improvement and immune modulation following recombinant Zoster vaccination in a patient with ME/CFS.
    AmirAli Bigleri, Emmanuel T Alimo, Amal Abouda +3
    Brain, behavior, & immunity - healthPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC
  2. Cutaneous Events After Recombinant Zoster Vaccination and Shoulder Injury Related to Zoster Vaccine Administration: A Narrative Review
    Carlo Ciccullo, Arturo Ciccullo, Sonia Farah +8
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMC
  3. Combined Vaccination with Recombinant HVT-ND and Live Newcastle Disease Vaccines Accelerates Early Immunity, Limits Virus Shedding and Reduces Transmission.
    Edit Kovács, Tímea Tatár-Kis, Balázs Felföldi +4
    VaccinesPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  4. Infections Following Skin Graft Surgery in Australia: Incidence, Graft Type and Anatomical Site Associations and Microbiology
    Semun Galimam, Naleesha Habib, Madhumitha Sangeetham Krishnan Asokumar +1
    Infectious disease reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Prevalence of Hepatitis C Infection and Treatment Initiation Following Dried Blood Spot Testing in New South Wales, Australia
    Annabelle Stevens, Anna Conway, Nigel Carrington +10
    Liver international : official journal of the International Association for the Study of the LiverPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{dawes2026shortterm,
  title = {{Short‐Term Adverse Events Following Recombinant Zoster Vaccination in Older Adults in Australia: A Survey Study Comparing Dose 1 and Dose 2 and Influence of Dose Interval}},
  author = {Lucy Dawes and Thuy Nguyen and Kristine Macartney and Lucy Deng},
  journal = {The Medical Journal of Australia},
  year = {2026},
  month = oct,
  doi = {10.5694/mja2.70327},
  url = {https://doi.org/10.5694/mja2.70327},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Short‐Term Adverse Events Following Recombinant Zoster Vaccination in Older Adults in Australia: A Survey Study Comparing Dose 1 and Dose 2 and Influence of Dose Interval
AU  - Lucy Dawes
AU  - Thuy Nguyen
AU  - Kristine Macartney
AU  - Lucy Deng
PY  - 2026
DA  - 2026/10/26
JO  - The Medical Journal of Australia
DO  - 10.5694/mja2.70327
UR  - https://doi.org/10.5694/mja2.70327
AB  - Self‐reported adverse events following first and second recombinant zoster vaccination (RZV) doses in older adults (n = 41,069) collected through AusVaxSafety were analysed. Adverse event rates were higher following Dose 2 (54%; 95% CI, 53%–54%) than after Dose 1 (45%; 95% CI, 45%–46%), particularly with 3–6‐ and 7–9‐month dose intervals, although medical review rates remained low (1.1%; 95% CI, 1.0%–1.2%), suggesting RZV is reactogenic but with no serious outcomes.
SN  - 0025-729X
SN  - 1326-5377
ER  -